Lumexa Imaging (NASDAQ:LMRI – Get Free Report) had its price target raised by Barclays from $13.00 to $17.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 13.17% from the company’s previous close.
Other analysts have also recently issued reports about the stock. Truist Financial started coverage on shares of Lumexa Imaging in a report on Monday, October 5th. They set a “buy” rating and a $18.00 target price for the company. KeyCorp initiated coverage on Lumexa Imaging in a research report on Thursday, September 24th. They set an “overweight” rating and a $18.00 price objective for the company. Raymond James Financial set a $19.00 price objective on Lumexa Imaging and gave the company a “strong-buy” rating in a research report on Wednesday, November 11th. Wall Street Zen raised Lumexa Imaging from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Finally, Weiss Ratings cut Lumexa Imaging from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Lumexa Imaging currently has an average rating of “Buy” and an average price target of $17.60.
Get Our Latest Stock Report on LMRI
Lumexa Imaging Stock Performance
Lumexa Imaging (NASDAQ:LMRI – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.19. Lumexa Imaging had a negative net margin of 1.96% and a negative return on equity of 2.93%. The business had revenue of $271.97 million for the quarter. Analysts forecast that Lumexa Imaging will post 0.22 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Lumexa Imaging
Several hedge funds have recently made changes to their positions in LMRI. Aquatic Capital Management LLC purchased a new position in Lumexa Imaging during the 3rd quarter worth approximately $77,000. Beck Mack & Oliver LLC raised its stake in Lumexa Imaging by 61.1% during the 3rd quarter. Beck Mack & Oliver LLC now owns 275,075 shares of the company’s stock valued at $2,820,000 after purchasing an additional 104,375 shares during the period. Pathstone Holdings LLC acquired a new stake in Lumexa Imaging during the 3rd quarter valued at $193,000. First Eagle Investment Management LLC purchased a new stake in shares of Lumexa Imaging in the third quarter valued at $4,753,000. Finally, Royce & Associates LP lifted its holdings in shares of Lumexa Imaging by 25.3% in the third quarter. Royce & Associates LP now owns 988,517 shares of the company’s stock valued at $10,132,000 after purchasing an additional 199,477 shares in the last quarter.
About Lumexa Imaging
Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.
Further Reading
- Five stocks we like better than Lumexa Imaging
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Lumexa Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumexa Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
